Conference Paper: Dysregulated expression of stem cell transcription factor Nanog in development and progress of ovarian cancers

File Download

re01.htm

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Obstetrics & Gynaecology: Conference papers
- Pathology: Conference papers

Title	Dysregulated expression of stem cell transcription factor Nanog in development and progress of ovarian cancers
Authors	Siu, MKY Wong, ESY Kong, DSH Wong, OGW Tam, KF Ngan, HYS Le, XF Cheung, ANY
Issue Date	2010
Publisher	American Association for Cancer Research.
Citation	The 101st Annual Meeting of the American Association for Cancer Research (AACR 2010), Washington D.C., 17-21 April 2010. [How to Cite?]
Abstract	Introduction: Ovarian cancer is the most lethal of all gynecological malignacies due to its lack of symptoms at early stages. In addition, widespread intraperitoneal metastases and malignant ascites frequently develop. Therefore, it is very important to identify novel prognostic and therapeutic targets for this cancer. Many researchers believe that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. Nanog is one of core transcription factors essential for the maintaining self-renewal and pluripotency in stem cells. This study investigated the clinical significance, functional roles and putative downstream targets of Nanog in ovarian cancer. Methods and Results: Differential protein expression profile of Nanog in clinical samples, including benign (n=6), borderline (n=7), carcinomas (n=97) and metastatic foci (n=24) were determined by immunohistochemistry. Differential mRNA expression pattern of Nanog in 3 normal ovarian epithelial cell lines, 16 ovarian cancer cell lines was assessed by quantitative real-time polymerase chain reaction. Subcellular localization of Nanog was performed by Western blotting. Nanog was found to be localized in the nucleus of ovarian cancers. High Nanog expression in ovarian cancers was significantly associated with high grade tumors, serous histological type and chemoresistance (p<0.05). Importantly, Nanog was found to be highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Elevated Nanog expression was associated with poor overall and disease-free survival in the univariate analysis. Nanog expression became one of the independent prognostic factors in the multivariate analysis for overall but not disease-free survival. By Transwell migration and invasion assays, stable knockdown of Nanog in ovarian cancer cell line, OVCAR-3, impeded cell migration and invasion. Stable knockdown of Nanog also increased mRNA expression of E-cadherin (an essential epithelial mesenchymal transition marker, thus related to metastasis) and FOXO1A (an important gene related to chemoresistance). Conclusion: Nanog was associated with progression of ovarian tumors, patients’ overall survival and chemoresistance, suggesting that Nanog can be one of the potential prognostic markers and therapeutic molecular targets in ovarian cancer.
Description	Poster Session 14 - PO.TB02.05: Cancer Stem Cell Biology 1: abstract no. 4233

DC Field	Value
dc.contributor.author	Siu, MKY
dc.contributor.author	Wong, ESY
dc.contributor.author	Kong, DSH
dc.contributor.author	Wong, OGW
dc.contributor.author	Tam, KF
dc.contributor.author	Ngan, HYS
dc.contributor.author	Le, XF
dc.contributor.author	Cheung, ANY
dc.date.accessioned	2010-12-23T08:43:24Z
dc.date.available	2010-12-23T08:43:24Z
dc.date.issued	2010
dc.description.abstract	Introduction: Ovarian cancer is the most lethal of all gynecological malignacies due to its lack of symptoms at early stages. In addition, widespread intraperitoneal metastases and malignant ascites frequently develop. Therefore, it is very important to identify novel prognostic and therapeutic targets for this cancer. Many researchers believe that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. Nanog is one of core transcription factors essential for the maintaining self-renewal and pluripotency in stem cells. This study investigated the clinical significance, functional roles and putative downstream targets of Nanog in ovarian cancer. Methods and Results: Differential protein expression profile of Nanog in clinical samples, including benign (n=6), borderline (n=7), carcinomas (n=97) and metastatic foci (n=24) were determined by immunohistochemistry. Differential mRNA expression pattern of Nanog in 3 normal ovarian epithelial cell lines, 16 ovarian cancer cell lines was assessed by quantitative real-time polymerase chain reaction. Subcellular localization of Nanog was performed by Western blotting. Nanog was found to be localized in the nucleus of ovarian cancers. High Nanog expression in ovarian cancers was significantly associated with high grade tumors, serous histological type and chemoresistance (p<0.05). Importantly, Nanog was found to be highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Elevated Nanog expression was associated with poor overall and disease-free survival in the univariate analysis. Nanog expression became one of the independent prognostic factors in the multivariate analysis for overall but not disease-free survival. By Transwell migration and invasion assays, stable knockdown of Nanog in ovarian cancer cell line, OVCAR-3, impeded cell migration and invasion. Stable knockdown of Nanog also increased mRNA expression of E-cadherin (an essential epithelial mesenchymal transition marker, thus related to metastasis) and FOXO1A (an important gene related to chemoresistance). Conclusion: Nanog was associated with progression of ovarian tumors, patients’ overall survival and chemoresistance, suggesting that Nanog can be one of the potential prognostic markers and therapeutic molecular targets in ovarian cancer.
dc.description.nature	link_to_OA_fulltext
dc.description	Poster Session 14 - PO.TB02.05: Cancer Stem Cell Biology 1: abstract no. 4233
dc.description.other	The 101st Annual Meeting of the American Association for Cancer Research (AACR 2010), Washington D.C., 17-21 April 2010.
dc.identifier.citation	The 101st Annual Meeting of the American Association for Cancer Research (AACR 2010), Washington D.C., 17-21 April 2010. [How to Cite?]
dc.identifier.hkuros	176675
dc.identifier.uri	http://hdl.handle.net/10722/129868
dc.language	eng
dc.publisher	American Association for Cancer Research.
dc.publisher.place	United States
dc.relation.ispartof	Annual Meeting of the American Association for Cancer Research
dc.title	Dysregulated expression of stem cell transcription factor Nanog in development and progress of ovarian cancers
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Siu, MKY</contributor.author><contributor.author>Wong, ESY</contributor.author><contributor.author>Kong, DSH</contributor.author><contributor.author>Wong, OGW</contributor.author><contributor.author>Tam, KF</contributor.author><contributor.author>Ngan, HYS</contributor.author><contributor.author>Le, XF</contributor.author><contributor.author>Cheung, ANY</contributor.author><date.accessioned>2010-12-23T08:43:24Z</date.accessioned><date.available>2010-12-23T08:43:24Z</date.available><date.issued>2010</date.issued><identifier.citation>The 101st Annual Meeting of the American Association for Cancer Research (AACR 2010), Washington D.C., 17-21 April 2010.</identifier.citation><identifier.uri>http://hdl.handle.net/10722/129868</identifier.uri><description>Poster Session 14 - PO.TB02.05: Cancer Stem Cell Biology 1: abstract no. 4233</description><description.abstract>Introduction: Ovarian cancer is the most lethal of all gynecological malignacies due to its lack of symptoms at early stages. In addition, widespread intraperitoneal metastases and malignant ascites frequently develop. Therefore, it is very important to identify novel prognostic and therapeutic targets for this cancer. Many researchers believe that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. Nanog is one of core transcription factors essential for the maintaining self-renewal and pluripotency in stem cells. This study investigated the clinical significance, functional roles and putative downstream targets of Nanog in ovarian cancer. Methods and Results: Differential protein expression profile of Nanog in clinical samples, including benign (n=6), borderline (n=7), carcinomas (n=97) and metastatic foci (n=24) were determined by immunohistochemistry. Differential mRNA expression pattern of Nanog in 3 normal ovarian epithelial cell lines, 16 ovarian cancer cell lines was assessed by quantitative real-time polymerase chain reaction. Subcellular localization of Nanog was performed by Western blotting. Nanog was found to be localized in the nucleus of ovarian cancers. High Nanog expression in ovarian cancers was significantly associated with high grade tumors, serous histological type and chemoresistance (p&lt;0.05). Importantly, Nanog was found to be highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Elevated Nanog expression was associated with poor overall and disease-free survival in the univariate analysis. Nanog expression became one of the independent prognostic factors in the multivariate analysis for overall but not disease-free survival. By Transwell migration and invasion assays, stable knockdown of Nanog in ovarian cancer cell line, OVCAR-3, impeded cell migration and invasion. Stable knockdown of Nanog also increased mRNA expression of E-cadherin (an essential epithelial mesenchymal transition marker, thus related to metastasis) and FOXO1A (an important gene related to chemoresistance). Conclusion: Nanog was associated with progression of ovarian tumors, patients&#8217; overall survival and chemoresistance, suggesting that Nanog can be one of the potential prognostic markers and therapeutic molecular targets in ovarian cancer.</description.abstract><language>eng</language><publisher>American Association for Cancer Research.</publisher><relation.ispartof>Annual Meeting of the American Association for Cancer Research</relation.ispartof><title>Dysregulated expression of stem cell transcription factor Nanog in development and progress of ovarian cancers</title><type>Conference_Paper</type><description.nature>link_to_OA_fulltext</description.nature><identifier.hkuros>176675</identifier.hkuros><publisher.place>United States</publisher.place><description.other>The 101st Annual Meeting of the American Association for Cancer Research (AACR 2010), Washington D.C., 17-21 April 2010.</description.other><bitstream.url>http://hub.hku.hk/bitstream/10722/129868/1/re01.htm</bitstream.url></item>